Study S001469

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Orforglipron Once Daily Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06584916
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 376
Start: 2024-09-13
Primary completion: 2025-11-21
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight
Interventions: DRUG:Orforglipron; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J2A-MC-GZPN

Registered primary outcomes

Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5 [Week 52]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004461	Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Aronne LJ, Nature medicine	2026	Randomized trial	PMID 42120723 DOI	cites ClinicalTrials.gov:NCT06584916; registry reference DERIVED:42120723